ClinicalTrials.gov
ClinicalTrials.gov Menu

Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00080015
Recruitment Status : Completed
First Posted : March 23, 2004
Last Update Posted : July 24, 2009
Sponsor:
Information provided by:
Ipsen

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : February 2005
  Actual Study Completion Date : February 2005